Paperpal Prime Logo

Haematologica : Impact Factor & More

eISSN: 1592-8721pISSN: 0390-6078
JournalOpen Access

Key Metrics

CiteScore
11.8
Eigenfactor
0.01 - 0.05
Impact Factor
10 - 15
Scite Index
0.90 5-Year SI
SJR
Q1Hematology
SNIP
2.03
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Haematologica

Haematologica Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher FERRATA STORTI FOUNDATION
Language English
Frequency Monthly
Article Processing ChargesEUR 3000
Publication Time8
Editorial Review ProcessPeer review
General Details
LanguageEnglish
Society/Institute/SponsorFerrata Storti Foundation
FrequencyMonthly
Publication Start Year1967
Publisher URLVisit website
Website URLVisit website
Publication Details
Other chargesVisit website
Publication Time 8
Editorial Review Detail
Editorial TeamVisit website
Review ProcessPeer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Haematologica ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Haematologica

Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".
  • 23 Jul 2026
  • Haematologica
Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".
  • 23 Jul 2026
  • Haematologica
Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.
  • 23 Jul 2026
  • Haematologica
Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial.
  • 23 Jul 2026
  • Haematologica
TAFRO-like syndrome associated with long-term CAR-T cell persistence after axicabtagene ciloleucel therapy.
  • 23 Jul 2026
  • Haematologica
Rapid recovery and functional resilience of bone marrow function post Bcell acute lymphoblastic leukemia.
  • 23 Jul 2026
  • Haematologica
Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".
  • 23 Jul 2026
  • Haematologica
Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".
  • 23 Jul 2026
  • Haematologica
Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.
  • 23 Jul 2026
  • Haematologica
Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial.
  • 23 Jul 2026
  • Haematologica
TAFRO-like syndrome associated with long-term CAR-T cell persistence after axicabtagene ciloleucel therapy.
  • 23 Jul 2026
  • Haematologica
Rapid recovery and functional resilience of bone marrow function post Bcell acute lymphoblastic leukemia.
  • 23 Jul 2026
  • Haematologica

FAQs on Haematologica